| 25.12 0.84 (3.46%) | 09-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 31.22 |
1-year : | 36.46 |
| Resists | First : | 26.72 |
Second : | 31.22 |
| Pivot price | 24.75 |
|||
| Supports | First : | 23.84 |
Second : | 22.05 |
| MAs | MA(5) : | 23.88 |
MA(20) : | 24.96  |
| MA(100) : | 21.93 |
MA(250) : | 17.86 |
|
| MACD | MACD : | 0 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 39.3 |
D(3) : | 26.3 |
| RSI | RSI(14): 54.3 |
|||
| 52-week | High : | 26.72 | Low : | 8.92 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BLFS ] has closed below upper band by 40.4%. Bollinger Bands are 1.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 25.46 - 25.57 | 25.57 - 25.66 |
| Low: | 24.27 - 24.38 | 24.38 - 24.49 |
| Close: | 24.94 - 25.12 | 25.12 - 25.29 |
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.
Sat, 14 Sep 2024
Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 20% Undervaluation? - Simply Wall St
Sat, 07 Sep 2024
BioLife Solutions, Inc. (NASDAQ:BLFS) Holdings Raised by Isthmus Partners LLC - MarketBeat
Thu, 05 Sep 2024
Investing in BioLife Solutions (NASDAQ:BLFS) a year ago would have delivered you a 78% gain - Yahoo Finance
Mon, 02 Sep 2024
134,194 Shares in BioLife Solutions, Inc. (NASDAQ:BLFS) Bought by Raymond James & Associates - MarketBeat
Fri, 30 Aug 2024
Why BioLife Solutions, Inc. (NASDAQ:BLFS) Could Be Worth Watching - Simply Wall St
Mon, 19 Aug 2024
BioLife Solutions (BLFS) Surpassed Revenue and Earnings-Per-Share Expectations in Q2 - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 46 (M) |
| Shares Float | 36 (M) |
| Held by Insiders | 2.9 (%) |
| Held by Institutions | 102.6 (%) |
| Shares Short | 3,920 (K) |
| Shares Short P.Month | 4,240 (K) |
| EPS | -1.45 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.96 |
| Profit Margin | -52.5 % |
| Operating Margin | -9.9 % |
| Return on Assets (ttm) | -7 % |
| Return on Equity (ttm) | -18.9 % |
| Qtrly Rev. Growth | -3.1 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 3.03 |
| EBITDA (p.s.) | -0.75 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 9 (M) |
| PE Ratio | -17.45 |
| PEG Ratio | -4.8 |
| Price to Book value | 3.6 |
| Price to Sales | 8.28 |
| Price to Cash Flow | -13798.1 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|